Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Bin Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-0729-074X; OpenAlex author ID A5072060416. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Single-Cell Sequencing Unravels Pancreatic Cancer: Novel Technologies Reveal Novel Aspects of Cellular Heterogeneity and Inform Therapeutic Strategies. Co-author DOI 10.3390/biomedicines13123024↗
  2. Exosomal SOX21-AS1 Regulates EREG by Sponging miR-451a and Promotes the Malignancy of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.95014↗
  3. Elderly Pancreatic Adenocarcinoma Cancer Patients Could Benefit From Postoperative Chemotherapy. Co-author DOI 10.1097/mpa.0000000000002214↗
  4. Impact of high-mobility-group A2 overexpression on epithelial-mesenchymal transition in pancreatic cancer. Co-author DOI 10.2147/cmar.s199289↗
  5. Decreased expression of MUC1 induces apoptosis and inhibits migration in pancreatic cancer PANC-1 cells via regulation of Slug pathway. Co-author DOI 10.3233/cbm-170297↗
  6. Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer. Co-author DOI 10.1007/s00268-013-2009-6↗
  7. Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice. Last author DOI 10.1007/s11033-013-2638-8↗
  8. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2012.11.015↗
  9. Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene. Co-author DOI 10.1002/cncr.27535↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xin Dong · 2 shared papers, 2013–2023 · strength 0.27
  2. Yulian Wu · 2 shared papers, 2013–2023 · strength 0.27
  3. Yiming Li · 1 shared paper, 2025 · strength 0.25
  4. Kexin Chen · 1 shared paper, 2025 · strength 0.25
  5. Tiancheng Xu · 1 shared paper, 2025 · strength 0.25
  6. Guanhu Yang · 1 shared paper, 2025 · strength 0.25
  7. Wenjie Lu · 1 shared paper, 2023 · strength 0.24
  8. Zhiyuan Hua · 1 shared paper, 2024 · strength 0.21
  9. Tu Dai · 1 shared paper, 2024 · strength 0.21
  10. Yong Yan · 1 shared paper, 2024 · strength 0.21
  11. Yongping Zhou · 1 shared paper, 2024 · strength 0.21
  12. Chuanzhen Hu · 1 shared paper, 2019 · strength 0.12
  13. Jian Gong · 1 shared paper, 2019 · strength 0.12
  14. Dansong Wang · 2 shared papers, 2012–2013 · strength 0.09
  15. Dayong Jin · 2 shared papers, 2012–2013 · strength 0.09
  16. Lianfang Lu · 1 shared paper, 2017 · strength 0.08
  17. Ping Zhao · 1 shared paper, 2017 · strength 0.08
  18. Wenhui Lou · 1 shared paper, 2013 · strength 0.05
  19. Xiu−Yan Huang · 1 shared paper, 2013 · strength 0.05
  20. Bin He · 1 shared paper, 2013 · strength 0.05
  21. Xin‐yu Qin · 1 shared paper, 2012 · strength 0.04
  22. Muxing Kang · 1 shared paper, 2013 · strength 0.03
  23. Qingqu Guo · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.